ArticleEmerging microbes & infections2024
In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis.
Article in Emerging microbes & infections, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Resistance development in KPC-producingMicrobiology spectrum · 2026Article
- Emergence of Ceftazidime-Avibactam-Induced KPC Variants (KPC-25/127) in Intracranial Infection and Implications for Clinical Management.MicrobiologyOpen · 2026Article
- Suboptimal ceftazidime-avibactam exposure drives sequentialMicrobiology spectrum · 2026Article
- Heterogeneous multicopy of blaNature communications · 2026Article
- Fitness cost of ceftazidime-avibactam resistance acquisition in carbapenem-resistant hypervirulent Klebsiella pneumoniae.BMC microbiology · 2026Article
- Evolution and high transferability of an IncN/FII plasmid harboring blaBMC microbiology · 2025Article
- Emergence of ceftazidime-avibactam resistance in clinical Klebsiella pneumoniae during therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- REL/DPA/AVI method: a novel approach for rapid detection of carbapenemase-producing Enterobacterales directly from positive blood cultures based on optical density.Journal of clinical microbiology · 2025Article
- Global epidemiology and resistance-related mutations of ceftazidime-avibactam-resistantFrontiers in cellular and infection microbiology · 2025Article
- Article
- A Comprehensive Overview ofInfection and drug resistance · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ceftazidime-avibactam (CZA) is employed for the treatment of infections caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.